# PharmaJet

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/pharmajet

- Industry: Medical Devices & Equipment
- Headquarters: Golden, US
- Website: www.pharmajet.com
- Total disclosed funding: $9.7M
- Latest round: Series F (Apr 20, 2018)
- Investors on record: 3

## About

PharmaJet, Inc. develops innovative needle-free injection systems, enhancing vaccine delivery and therapeutic efficacy for healthcare providers and pharmaceutical manufacturers globally.Founded in 2005 and headquartered in Golden, US, PharmaJet, Inc. focuses on needle-free delivery solutions. The company has engaged in 12 deals, with the latest deal on October 13, 2023, during a Series G funding round, raising USD 1.790 mn, bringing the total amount raised to USD 1.790 mn and valuing the company at USD 88.209 mn. The founders are Heather Callender-Potters and Kathleen Callender, with Chris Cappello serving as CEO.PharmaJet specializes in needle-free injection systems designed for the effective delivery of vaccines and therapeutics. Their main products, the Tropis® ID Needle-free System and the Stratis® IM/SC Needle-free System, facilitate intradermal, intramuscular, and subcutaneous injections, providing a needle-free option for administering vaccines. These systems have proven effective in enhancing immunogenicity for applications in nucleic acid vaccines, oncology, COVID-19, polio, and influenza. PharmaJet's offerings are backed by WHO PQS certification and CE Mark approval, validating their use in over 20 countries and supporting a diverse clientele that includes pharmaceutical companies and healthcare providers across North America, Europe, Asia, and Africa.PharmaJet derives its revenue primarily through B2B partnerships with pharmaceutical companies. The company's sales model involves direct transactions for its needle-free systems, structured around customized agreements that include product sales and technical support. Their flagship products, the Tropis® and Stratis® systems, facilitate bulk orders for clinical and commercial applications, fostering long-term partnerships with clients to enhance vaccine and therapeutic delivery. Their approach ensures that they meet specific client requirements from preclinical development through to commercial launch, maintaining strong demand from a growing list of pharmaceutical partners.In October 2023, PharmaJet, Inc. raised funding from new investor Daicel Corporation, which will be utilized to continue developing their business and strengthening partnerships. The company aims to enhance its product offerings, focusing on new needle-free delivery solutions. Additionally, PharmaJet plans to expand into new geographic markets, particularly targeting regions in Asia and Africa by the end of 2024.

## Funding rounds

- Series F, Apr 20, 2018, $6.7M — Rockies Venture Fund, MedTech Innovator, Stout Street Capital
- Series E, Jan 21, 2016, $3M — Rockies Venture Fund

## Investors

- Rockies Venture Fund (https://capitalatlas.ai/funds/rockies-venture-fund) — Series E, Series F
- MedTech Innovator — Series F
- Stout Street Capital (https://capitalatlas.ai/funds/stout-street-capital) — Series F